Topic: Tarceva
Pfizer ends study on potential lung cancer drug, committee says it won't meet treatment goalPfizer Inc. said Thursday it discontinued a late-stage study of the drug candidate figitumumab in patients with late-stage lung cancer, citing a lack of effectiveness. The company said ...
A new category of drug brakes the growth of treatment-resistant lung cancer among lab mice, according to a study published on Thursday in the science journal Nature. The new type could add powerfully to a small family of drugs called epidermal growth ...